ORPHA:449
Hepatoblastoma
Publications
15,123
Trials
51
Interventional, condition-specific
Researchers
1,365
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A malignant hepatic tumor, typically affecting the pediatric population, arising mostly in an otherwise healthy liver. The most common signs are abdominal distension and abdominal mass. Sometimes patients present with anorexia, weight loss, fatigue. Most HBLs are sporadic, but some cases are associated with genetic factors, especially overgrowth syndromes, such as Beckwith-Wiedemann syndrome (BWS) or hemihypertrophy, and familial adenomatous polyposis (FAP).
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018666
- MeSH:D018197
- UMLS:C0206624
- NCIT:C3728
Additional Mondo synonyms (7)
HBL · hepatoblastoma · hepatoblastoma, malignant · paediatric embryonal hepatoma · paediatric hepatoblastoma · pediatric embryonal hepatoma · pediatric hepatoblastoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
15,123 matched papers (8,514 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
51 matched on ClinicalTrials.gov (11 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
15,123
15,123 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
15,123 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
8,514 in the last 10 years · low confidence
Phrase hits: 15,123 · MeSH hits: 0
Who's working on it?
1,365
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Branchereau S8 papers · 2026
Paediatric Surgery Unit, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
Papers in Europe PMC - 02Hiyama E7 papers · 2026
Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan.
Papers in Europe PMC - 03Liu J7 papers · 2026
Hepatobiliary and Gastrointestinal Department of PLA Rocket Force Characteristic Medical Center, Beijing 100086, China.
Papers in Europe PMC - 04Ranganathan S7 papers · 2026
Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Papers in Europe PMC - 05Hirsch TZ6 papers · 2026
Centre de Recherche des Cordeliers, Paris, France; Institut du Cancer Paris CARPEM, AP-HP, Department of Oncology, Hopital Européen Georges Pompidou, F-75015, Paris, France.
Papers in Europe PMC - 06Liu Y6 papers · 2026
Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: spu_liuy@163.com.
Papers in Europe PMC - 07O'Neill AF6 papers · 2026
Department of Pediatric Oncology, Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 08Wang H6 papers · 2026
Department of Surgical Oncology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Papers in Europe PMC - 09Zhang Y6 papers · 2026
Beijing National Laboratory for Molecular Sciences and MOE Key Laboratory of Bioorganic Chemistry and Molecular Engineering, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
Papers in Europe PMC - 10Alaggio R5 papers · 2026
Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital IRCCS, Rome, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
51
interventional trials for this specific condition
51 interventional trials matched this specific condition name; 11 currently recruiting in our sample.
Data as of 27 July 2026
51 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.1th percentile).
low confidence · 97.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
51 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04851119·RECRUITING·Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Conditions: Colorectal Carcinoma · Endometrial Carcinoma · Melanoma · Neuroblastoma·Matched via name phrase
- NCT07300449·RECRUITING·A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
Conditions: Hepatoblastoma·Matched via name phrase
- NCT04308330·RECRUITING·Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Conditions: Ewing Sarcoma · Rhabdomyosarcoma · Wilms Tumor · Neuroblastoma·Matched via name phrase
- NCT04634357·RECRUITING·ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Conditions: Hepatoblastoma · Hepatocellular Carcinoma (HCC) · Liver Neoplasms · Metastatic Liver Cancer·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT04901702·RECRUITING·Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Conditions: Recurrent Solid Tumor · Recurrent Ewing Sarcoma · Recurrent Hepatoblastoma · Recurrent Malignant Germ Cell Tumor·Matched via name phrase
- NCT04478292·RECRUITING·A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
Conditions: Hepatoblastoma·Matched via name phrase
- NCT06198296·RECRUITING·Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Conditions: Hepatoblastoma · Hepatocellular Carcinoma · Wilms Tumor · Malignant Rhabdoid Tumor·Matched via name phrase
- NCT04897321·RECRUITING·B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Conditions: Pediatric Solid Tumor · Osteosarcoma · Rhabdomyosarcoma · Neuroblastoma·Matched via name phrase
- NCT07148050·RECRUITING·Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Conditions: Solid Tumor (Excluding CNS) · Liver Cell Carcinoma · Malignant Rhabdoid Tumor · Yolk Sac Tumor·Matched via name phrase
- NCT07188311·RECRUITING·Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
Conditions: Hepatoblastoma · Pediatric Cancer·Matched via name phrase
Observational and natural-history studies
13 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05556642·RECRUITING·Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
Conditions: Relapsed Hepatoblastoma · Refractory Hepatoblastoma·Matched via name phrase
- NCT06541652·RECRUITING·A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Conditions: Hepatocholangiocarcinoma · Fibrolamellar Carcinoma · Hepatic Epithelioid Hemangioendothelioma · Hepatoblastoma·Matched via name phrase
- NCT06822842·NOT YET RECRUITING·Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models
Conditions: Neuroblastoma · Medulloblastoma · Wilms Tumor · Hepatoblastoma·Matched via name phrase
- NCT03959800·RECRUITING·Molecular Basis of Pediatric Liver Cancer
Conditions: Childhood Liver Cancer · Liver Malignant Tumors · Embryonal Sarcoma of Liver (Disorder) · Hepatoblastoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hepatoblastoma" OR "hepatoblastoma, malignant" OR "paediatric embryonal hepatoma" OR "paediatric hepatoblastoma" OR "pediatric embryonal hepatoma" OR "pediatric hepatoblastoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hepatoblastoma" OR "hepatoblastoma, malignant" OR "paediatric embryonal hepatoma" OR "paediatric hepatoblastoma" OR "pediatric embryonal hepatoma" OR "pediatric hepatoblastoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 51 interventional · 13 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: HBL
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (15123) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T13:52:30.227Z
